BEZ235, a novel therapeutic agent that targets two molecules, including PI3K and mTOR in the PI3K/Akt/mTOR pathway [10], has demonstrated efficacy as an anti-tumour agent in vitro and in vivo in several cancers [3, 4, 11–12]. Here, PIK3CA is linked to cancer.